 Heres a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks Biotech Stocks Hitting 52-week Highs June 18 ADC Therapeutics SA NYSE: ADCT Adverum Biotechnologies Inc NASDAQ: ADVM Alpine Immune Sciences Inc NASDAQ: ALPN announced a licensing agreement with AbbVie Inc NYSE: ABBV Amicus Therapeutics, Inc. NASDAQ: FOLD Biohaven Pharmaceutical Holding Co Ltd NYSE: BHVN BioMarin Pharmaceutical Inc. NASDAQ: BMRN BioXcel Therapeutics Inc NASDAQ: BTAI Burning Rock Biotech Ltd NASDAQ: BNR Castle Biosciences Inc NASDAQ: CSTL Cytokinetics, Inc. NASDAQ: CYTK DiaMedica Therapeutics Inc NASDAQ: DMAC Fennec Pharmaceuticals Inc NASDAQ: FENC Neoleukin Therapeutics Inc NASDAQ: NLTX Neubase Therapeutics Inc NASDAQ: NBSE Ocular Therapeutix Inc NASDAQ: OCUL Ovid Therapeutics Inc NASDAQ: OVID Passage Bio Inc NASDAQ: PASG Pliant Therapeutics Inc NASDAQ: PLRX Protagonist Therapeutics Inc NASDAQ: PTGX Royalty Pharma plc NASDAQ: RPRX IPOed Monday Sarepta Therapeutics Inc NASDAQ: SRPTannounced a licensing agreement with Selecta Biosciences Inc NASDAQ: SELB for licensing the latters immune tolerance platform, ImmTOR for use in Duchenne muscular dystrophy and certain limb-girdle muscular dystrophies Tandem Diabetes Care Inc NASDAQ: TNDM TELA Bio Inc NASDAQ: TELA TFF Pharmaceuticals Inc NASDAQ: TFFP Trevena Inc NASDAQ: TRVN Zentalis Pharmaceuticals Inc NASDAQ: ZNTLDown In The Dumps Biotech Stocks Hitting 52-week Lows June 18 CALLIDITAS THERS ADR NASDAQ: CALTStocks In Focus Mylan Wins Patent Lawsuit Against Biogen With Respect To Multiple Sclerosis Drug Mylan NV NASDAQ: MYL said the U.S. District Court for the Northern District of West Virginia ruled in its favor by invalidating Biogen Incs NASDAQ: BIIB Tecfidera patent, U.S. Patent No. 8,399,514, for lack of written description. Mylan noted that the patent pertains to methods of treating multiple sclerosis using a dose of 480 mgday of dimethyl fumarate delayed release capsules, and would have disallowed generic competition until 2028.With the patent win, Mylan is allowed to launch of its dimethyl fumarate product upon the receipt of FDA approval.In pre-market trading Friday, Mylan shares were rising 2.27 to 16.70.Assembly Biosciences Regains Rights To Gastrointestinal Programs After AbbVie Terminates Deal Assembly Biosciences Inc NASDAQ: ASMB said it will regain worldwide rights to all microbiome gastrointestinal programs, including ABI-M201 and ABI-M301, licensed under its collaboration agreement with AbbVies Allergan. The development follows AbbVie deciding to terminate the RD;, collaboration and license agreement. This decision was not based on any efficacy, safety, or other data related to the collaboration programs, Assembly Biosciences said.ABI-M201 is currently being evaluated in a Phase 1b trial in patients with mild to moderate ulcerative colitis and ABI-M301 is a preclinical program for Crohns disease, the company said. The transition is expected to be completed in the fourth quarter of 2020.In pre-market trading, Assembly Biosciences shares were rising 1.95 to 22.50.Tiziana to Get Patent For Platform Technology For Oral Administration Of Fully Human Monoclonal Antibodies Tiziana Life Sciences plc NASDAQ: TLSA announced the United States Patent and Trademark Office has granted a patent covering its proprietary platform technology for the oral administration of Foralumab, its proprietary fully human monoclonal antibody, and all other anti-CD3 monoclonal antibodies. The CD3 cluster of differentiation 3 is a protein complex on T-cells, which is important for regulation of immune system, the company added. The patent will be issued by the USPTO June 23.The stock rallied 16.09 to 7 in pre-market trading.Roche Reports Positive Results For Late-Stage Prostate Cancer Study Roche Holdings AG Basel ADR OTC: RHHBY said the phase 3 IPATential150 study that evaluated ipatasertib in combination with abiraterone and prednisoneprednisolone compared to current standard-of-care plus placebo met its co-primary endpoint of radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer and whose tumours had PTEN loss.The company said overall survival benefit and additional secondary endpoints are not yet mature and the trial will continue until the next planned analysis.Endologix CFO Departs, Announces Interim CEO Endologix, Inc. NASDAQ: ELGX said its CFO Vaseem Mahboob,will leave the company, effective July 1, to take over as CFO of a private global healthcare company.View more earnings on IBBThe company announced the appointment of Cindy Pinto, VP, Financial Planning Analysis, as interim CFO in addition to her current responsibilities, and it also said it has initiated a search process for a permanent successor.Miragen Appoints Pharma Industry Veteran As COO Miragen Therapeutics Inc NASDAQ: MGEN announced the appointment of Lee Rauch as Chief Operating Officer, effective immediately. Rauch, who has over 25 years of experience in the biotech and pharma industries, will report to the CEO and will be responsible for overseeing business development, licensing, partnerships, investor relations, corporate communications, intellectual property, and new product planning, the company said.In pre-market trading, the stock was up 4.20 t 1.24.Akebia Names David Spellman as CFO Akebia Therapeutics Inc NASDAQ: AKBA said David Spellman is joining Akebia as its new SVP, Chief Financial Officer and Treasurer, effective June 29, replacing Jason Amello, who has been serving in the position since 2013.Dynavax Says Human Trial of COVID-19 Vaccine Using Its Adjuvant Initiated Dynavax Technologies Corporation NASDAQ: DVAX announced the first participants have been dosed in the Phase 1 clinical trial to evaluate Clover Biopharmas vaccine candidate to prevent COVID-19 that contains the Companys CpG 1018 adjuvant.In pre-market trading, Dynavax shares were rising 9.30 to 6.70.Earnings Urovant Sciences Ltd NASDAQ: UROV reported a net loss of 1.68 per share for its fiscal-year 2019 fourth quarter compared to a loss of 96 cents per share a year ago. This was wider than the consensus loss estimate of 1.24 per share.The stock was down 3.48 to 11.10 in pre-market trading.BioNano Genomics Incs NASDAQ: BNGO first-quarter revenues fell from 1.8 million in 2019 to 1.1 million in 2020. The net loss widened from 7.8 million to 10.5 million.The stock was sliding 5.80 to 49 cents in pre-market trading.On The Radar PDUFA Dates Nabriva Therapeutics PLC - ADR NASDAQ: NBRV is knocking at the FDA altar for the second time for its investigational antibiotic contepo for treating complicated urinary tract infection. The company hinted at the decision being delayed due to the FDA requiring inspection of the facilities of third-party manufacturers in Europe.Evoke Pharma Inc NASDAQ: EVOK has a PDUFA date in the unfolding for its Gimoti to treat women with acute and recurrent diabetic gastroparesis.IPOs Repare Therapeutics Inc., a precision oncology company enabled by its proprietary synthetic lethality approach, priced its upsized initial public offering of 11 million shares of its common shares at 20 per share. Repares common shares are expected to begin trading on the Nasdaq under the ticker symbol RPTX.Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, priced its IPO of 13.88 million shares at 20 per share. The shares are expected to begin trading on the Nasdaq under the ticker symbol FMTX.See more from Benzinga The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahns Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions The Daily Biotech Pulse: Patent Win For Amarin, FDA Nod For Novartis Merck, Chembios Coronavirus EUA Revoked The Daily Biotech Pulse: GlaxoSmithKline, IDEAYA Strike Oncology Partnership, Decision Day For Merck, Adverums New CEOC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 